FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

717178009: Reslizumab (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2016. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3308594018 Reslizumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
3308595017 Reslizumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
373391000195114 reslizumab it Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
837871000172119 reslizumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Reslizumab (substance) Is a Respiratory system agent (substance) true Inferred relationship Some
Reslizumab (substance) Is a agent d'anticorps monoclonal false Inferred relationship Some
Reslizumab (substance) Is a Monoclonal antibody true Inferred relationship Some
Reslizumab (substance) Is a Substance with interleukin 5 receptor antagonist mechanism of action (substance) true Inferred relationship Some
Reslizumab (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Interleukin 5 receptor antagonist true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing only reslizumab in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Reslizumab (substance) Inferred relationship Some 1
Product containing reslizumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Reslizumab (substance) Inferred relationship Some 1
Reslizumab only product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Reslizumab (substance) Inferred relationship Some 1
Reslizumab-containing product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Reslizumab (substance) Inferred relationship Some 1

This concept is not in any reference sets

Back to Start